Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in
Status
ACTIVE
Global HQ
Chicago, United States
Countries of investment
  • United States
  • China
  • United Kingdom
Investment stages
  • Seed
  • Series A
  • Series B
Industries
  • Life Sciences
  • Biotechnology
About
ARCH Venture Partners champions audacious, science-driven entrepreneurship by investing in companies emerging from academic and national labs, particularly in biotech and strategic physical sciences like semiconductors. Since 1986, it has taken a long-term, contrarian stance, favoring imaginative, transformative technology ventures rather than short-term trends and helps them mature through sustained support.
Min check size
$500K
Max check size
$10M
Fund size
NPS

Investment Thesis

ARCH Venture Partners backs pioneering science-based companies with the potential to redefine industries. The firm partners closely with founders emerging from academic and research ecosystems. Its strategy is rooted in advancing breakthrough technologies that drive long-term transformation.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

ARCH Venture Partners features seasoned managing directors and partners with long tenures in venture capital, entrepreneurship, law, and finance, many with 10+ years of experience along with deep technical backgrounds.

ARCH Venture Partners Contacts Information

Primary contact

Secondary contact

Team

Robert Nelsen – Co-founder & Managing Director

Keith Crandell – Co-founder & Managing Director

Kristina Burow – Managing Director

Paul Berns – Managing Director

Clinton Bybee – Co-founder & Managing Director

Portfolio

908 Devices

Accompany Health

Aera Therapeutics

Agios Pharmaceuticals

AIRNA

Akamis Bio

Aledade

Alnylam Pharmaceuticals

Altos Labs

Arbor Biotechnologies

Areteia Therapeutics

Arsenal Biosciences

Aspen Neuroscience

Autobahn Therapeutics

Basking Biosciences

BE Biopharma

Beam Therapeutics

Bit Bio

Bitterroot Bio

Boundless Bio

Brii Biosciences

Carrick Therapeutics

City Therapeutics

CStone Pharmaceuticals

Curie Bio

Cytrellis Biosystems

Denali Therapeutics

Dewpoint Therapeutics

Dispatch Biotherapeutics

eGenesis

Elephas Biosciences

Encoded Therapeutics

Encodia

Enumerix

EQRx (Acquired)

Erasca

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp